Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.
Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gebski VJ, Elez E, Nott LM, Karapetis CS, Lunke S, Chantrill LA, Pavlakis N, Khasraw M, Underhill C, Ciardiello F, Jefford M, Wasan H, Haydon A, Price TJ, van Hazel G, Wilson K, Simes J, Shapiro JD. Segelov E, et al. Among authors: van hazel g. J Clin Oncol. 2016 Jul 1;34(19):2258-64. doi: 10.1200/JCO.2015.65.6843. Epub 2016 Apr 25. J Clin Oncol. 2016. PMID: 27114605 Clinical Trial.
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ. Tebbutt NC, et al. Among authors: van hazel ga. J Clin Oncol. 2010 Jul 1;28(19):3191-8. doi: 10.1200/JCO.2009.27.7723. Epub 2010 Jun 1. J Clin Oncol. 2010. PMID: 20516443 Clinical Trial.
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.
Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IA; NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group. Karapetis CS, et al. Clin Cancer Res. 2014 Feb 1;20(3):744-53. doi: 10.1158/1078-0432.CCR-13-0606. Epub 2013 Nov 11. Clin Cancer Res. 2014. PMID: 24218517 Clinical Trial.
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.
Shapiro JD, Thavaneswaran S, Underhill CR, Robledo KP, Karapetis CS, Day FL, Nott LM, Jefford M, Chantrill LA, Pavlakis N, Tebbutt NC, Price TJ, Khasraw M, Van Hazel GA, Waring PM, Tejpar S, Simes J, Gebski VJ, Desai J, Segelov E. Shapiro JD, et al. Among authors: van hazel ga. Clin Colorectal Cancer. 2018 Dec;17(4):313-319. doi: 10.1016/j.clcc.2018.06.002. Epub 2018 Jun 8. Clin Colorectal Cancer. 2018. PMID: 30463680 Clinical Trial.
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
Segelov E, Waring P, Desai J, Wilson K, Gebski V, Thavaneswaran S, Elez E, Underhill C, Pavlakis N, Chantrill L, Nott L, Jefford M, Khasraw M, Day F, Wasan H, Ciardiello F, Karapetis C, Joubert W, van Hazel G, Haydon A, Price T, Tejpar S, Tebbutt N, Shapiro J. Segelov E, et al. Among authors: van hazel g. BMC Cancer. 2016 May 31;16:339. doi: 10.1186/s12885-016-2389-8. BMC Cancer. 2016. PMID: 27246726 Free PMC article. Clinical Trial.
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.
Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, Dutton P, Love S, Gebski V, Gray A; FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators; van Hazel G, Sharma RA. Wasan HS, et al. Among authors: van hazel g. Lancet Oncol. 2017 Sep;18(9):1159-1171. doi: 10.1016/S1470-2045(17)30457-6. Epub 2017 Aug 3. Lancet Oncol. 2017. PMID: 28781171 Free PMC article. Clinical Trial.
Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.
van Hazel GA, Pavlakis N, Goldstein D, Olver IN, Tapner MJ, Price D, Bower GD, Briggs GM, Rossleigh MA, Taylor DJ, George J. van Hazel GA, et al. J Clin Oncol. 2009 Sep 1;27(25):4089-95. doi: 10.1200/JCO.2008.20.8116. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652069 Clinical Trial.
Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.
Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC. Price TJ, et al. Among authors: van hazel ga. Ann Oncol. 2012 Jun;23(6):1531-6. doi: 10.1093/annonc/mdr488. Epub 2011 Oct 29. Ann Oncol. 2012. PMID: 22039086 Free article. Clinical Trial.
Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.
Vickers MM, Karapetis CS, Tu D, O'Callaghan CJ, Price TJ, Tebbutt NC, Van Hazel G, Shapiro JD, Pavlakis N, Gibbs P, Blondal J, Lee U, Meharchand JM, Burkes RL, Rubin SH, Simes J, Zalcberg JR, Moore MJ, Zhu L, Jonker DJ. Vickers MM, et al. Among authors: van hazel g. Ann Oncol. 2013 Apr;24(4):953-60. doi: 10.1093/annonc/mds577. Epub 2012 Nov 8. Ann Oncol. 2013. PMID: 23144444 Free article. Clinical Trial.
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
Price TJ, Bruhn MA, Lee CK, Hardingham JE, Townsend AR, Mann KP, Simes J, Weickhardt A, Wrin JW, Wilson K, Gebski V, Van Hazel G, Robinson B, Cunningham D, Tebbutt NC. Price TJ, et al. Among authors: van hazel g. Br J Cancer. 2015 Mar 17;112(6):963-70. doi: 10.1038/bjc.2015.37. Br J Cancer. 2015. PMID: 25742472 Free PMC article. Clinical Trial.
93 results